Sandoz CEO Richard Saynor predicts biosimilars referencing semaglutide to enter the Canadian market in early in 2026, as the patent protection for Novo Nordisk’s blockbuster drug looms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback